Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Under offer .Long way to go.
Give up Pigman you just seem desperate and bitter now.
How’s the FAB working out for ya Porky Pie…You’re no stranger to placing as FAB had an eye watering 84% discounted placing last year, oh and another placing this year. Enjoy Porker… 😂😂😂
It should read that it would not surprise me.
Cash until Feb 2025 PLUS
The number of prospective clients in the sales pipeline for Inaphaea's services and products is continuing to grow, with 11 at an advanced stage of discussion. This includes both screening and licencing of patient derived cells ("PDC"). Interest has been expressed from a range of end users, including biotech companies, large pharma and large CROs
PLUS
Deals for Val 201 and CLX possible.
PLUS a larger market cap with so much news. We could be 20p plus by then. A few evaluations to conclude in the next 6 months as well including and possibly Imperial as like Cathy said that was at a fairly advanced stage.
If they can present like this to an institution It would surprise me if they can get some buyers through the open market.
@mornington yep my average is 20, not quite 50 but still a 500% increase on today's closing price. still not decided whether to be cutting my losses while I'm *only* 80% down or just forget about it and hope for a miracle haha
@darientaylor
Good to check the RNS first before posting.
With new work coming in we have enough cash and i think we will get either val 201 or Kings done. NO placing again!
16 May 2024
VALIRX PLC
("ValiRx" or the "Company")
Further re Final Results
ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, announces that, following the publication of its audited results for the year ended 31 December 2023 on 15 May 2024 and shareholder feedback and communication, a clarification as to its cash position and recent fundraising activities.
As stated in the announcement of 15 May 2024, the cash balance of the Company as at 31 December 2023 was £174,684. Subsequent to the financial year end and as set out in the same announcement, the Company raised approximately £1.8m, before expenses, through the issue of new ordinary shares in January 2024. As at 15 May 2024, the Company's cash position was approximately £1.1m.
Placing ahoy!!
Inaphaea BioLabs
Commercial Update
The number of prospective clients in the sales pipeline for Inaphaea's services and products is continuing to grow, with 11 at an advanced stage of discussion. This includes both screening and licencing of patient derived cells ("PDC"). Interest has been expressed from a range of end users, including biotech companies, large pharma and large CROs
Very good update today with 11 prospective clients mentioned today
This was the original purpose/details of using Inaphea
Dr Jim Millen, CEO at Physiomics commented "The Collaborative Service Agreement will expand the scope of our core consulting business to discovery stage projects and improve our access to clients focused on earlier stages of drug development, while at the same time supporting Inaphaea's own service offering. The synergy is clear and both the scientific and commercial ambitions of our two companies are well matched. We look forward to working closely with ValiRx through this initiative"
Dr Suzy Dilly, CEO at ValiRx explains "The Collaborative Services Agreement is the first step towards converting Inaphaea into a true tCRO®. The Physiomics modelling skills will enable our clients to interpret and build on the data generated within the Inaphaea facility. I am delighted to be able to offer this additional service module to our clients. This additional value-added service will be available to our first service users, with benefits expected to increase as more complex data generation technologies are added to our capabilities"
Some people have an average of 50.00+ so a long way to go yet.
And RSI only 63. It has been up as high as 97 back in April 2020
Looking forward to this week...
Blasted the Gap, the 50 DMA (which is now starting to rise), so early stages of a set-up for a Golden X.
Interest in this share is large historically
GLA
Well done to all holders today, long termers or those in for a quick trade 👏 suck it up Porky 🤡
Do I detect a dose of sour grapes porky....Don't think anyones scared enough to listen to you any more... TA TA old bean
LMOL
Winner Winner Chicken Dinner, roll up, roll up.
Fools rush in but if it helps those trapped its a good thing.
They haven't found a CEO yet, what next: betting on two snails to see which one beats the other in a race.
Ridiculous
Ripley, we closed at 3.9- 4.1
Midday RNS and 70% up to close at 3.6p , my broker has it wrong again showing down 13% , maybe that was Friday .
What a buy this would of been last week when it went under 2p.
My large 12/3/24 might be in profit next few days .
The casino does swing both ways , in fact twice as much up as the 30% one day falls I noticed .
LOL!!!
What did i tell you all?
4p!!!
This week we hit 8p! GAP FILL!
THEN 10/11P!
GLA/DYR!
I highlighted 3 ways to get this to double digits with further potential for other news such as the 401 conclusion.
I think the first one is a dead cert now with so many clients waiting. 11 at the advanced stage so hopefully lots of RNS's in the coming weeks for significant upside from here.
201 and CLX are either progressing well or ongoing but even with a 5050 shot you could be looking at 500% plus from here if either came good in the next few weeks/months.
Therefore I feel very bullish that the plan will work out well. Love the low risk strategy just need to get this sold to large clients and bring them in to get closer to fair value. We all win when one of many gets a deal.
With so much time left and revenue to come hopefully from different sources I think we can only look up from here. Keep going and we may get to 10p plus in the coming weeks.
Val 201 the gift that never gives!
Very well written summary...quite why they didn't say all this in the results outlook statement is puzzling
Great rise though
Expecting 15p minimum by December and that would be just a 20 million market cap. If CLX gets signed then all bets are off.